Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2Phase NA 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1

Interventions

Blood Specimen Collection 106Standard of Care 81Exercise 68Radiotherapy 54Radiosurgery 47Magnetic Resonance Spectroscopy 46Specimen Handling 45Surveys and Questionnaires 43Practice Guidelines as Topic 43Interviews as Topic 43Educational Status 42Methods 41Drug Therapy 34Early Intervention, Educational 30Surgical Procedures, Operative 29Palliative Care 25Biopsy 24Control Groups 21venetoclax 17Patient Navigation 17Cisplatin 17Therapeutics 16Proton Therapy 15Magnetic Resonance Imaging 15Behavior Therapy 15Neoadjuvant Therapy 14Cognitive Behavioral Therapy 13Acupuncture Therapy 13Resistance Training 12Nutritional Status 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × aumolertinib × Clear all
NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Kunming Medical University

Phase NA Recruiting
30 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡